Akari Therapeutics (AKTX) to Release Quarterly Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) will likely be announcing its Q4 2025 results after the market closes on Tuesday, April 7th. Analysts expect the company to announce earnings of ($0.0450) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.65).

Akari Therapeutics Price Performance

Shares of AKTX stock opened at $4.47 on Monday. The business has a 50-day moving average price of $8.54 and a two-hundred day moving average price of $17.38. Akari Therapeutics has a 12-month low of $4.16 and a 12-month high of $63.20.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 5.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AKTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. LADENBURG THALM/SH SH assumed coverage on shares of Akari Therapeutics in a research report on Monday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. Finally, HC Wainwright lifted their price target on shares of Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $89.00.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.